Beam Therapeutics(US:BEAM) ZACKS·2025-10-28 16:46Core Viewpoint - The market anticipates Beam Therapeutics Inc. (BEAM) to report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Beam Therapeutics is expected to report a quarterly loss of $0.98 per share, reflecting a year-over-year change of +16.2%, while revenues are projected to be $12.99 million, down 9% from the previous year [3]. - The consensus EPS estimate has been revised 5.19% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Beam Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.41%, indicating bearish sentiment among analysts [12]. - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 2, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Beam Therapeutics was expected to post a loss of $1.04 per share but delivered a loss of -$1.00, resulting in a surprise of +3.85% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Sarepta Therapeutics (SRPT) is expected to post a loss of $0.03 per share for the same quarter, indicating a year-over-year change of -104.8%, with revenues expected to be $346.23 million, down 25.9% [18]. - Sarepta's consensus EPS estimate has been revised 13.1% higher in the last 30 days, resulting in a positive Earnings ESP of +1,733.32%, suggesting a likely earnings beat [19][20].